TY - JOUR
T1 - Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome
AU - Tiedemann, Rodger E.
AU - Zhu, Yuan Xao
AU - Schmidt, Jessica
AU - Shi, Chang Xin
AU - Sereduk, Chris
AU - Yin, Hongwei
AU - Mousses, Spyro
AU - Stewart, A. Keith
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Despite recent advances in targeted treatments for multiple myeloma, optimal molecular therapeutic targets have yet to be identified. To functionally identify critical molecular targets, we conducted a genome-scale lethality study in multiple myeloma cells using siRNAs. We validated the top 160 lethal hits with four siRNAs per gene in three multiple myeloma cell lines and two non-myeloma cell lines, cataloging a total of 57 potent multiple myeloma survival genes. We identified the Bcl2 family member MCL1 and several 26S proteasome subunits among the most important and selective multiple myeloma survival genes. These results provided biologic validation of our screening strategy. Other essential targets included genes involved in RNA splicing, ubiquitination, transcription, translation, and mitosis. Several of the multiple myeloma survival genes, especially MCL1, TNK2, CDK11, and WBSCR22, exhibited differential expression in primary plasma cells compared with other human primary somatic tissues. Overall, the most striking differential functional vulnerabilities between multiple myeloma and non-multiple myeloma cells were found to occur within the 20S proteasome subunits, MCL1, RRM1, USP8, and CKAP5. We propose that these genes should be investigated further as potential therapeutic targets in multiple myeloma.
AB - Despite recent advances in targeted treatments for multiple myeloma, optimal molecular therapeutic targets have yet to be identified. To functionally identify critical molecular targets, we conducted a genome-scale lethality study in multiple myeloma cells using siRNAs. We validated the top 160 lethal hits with four siRNAs per gene in three multiple myeloma cell lines and two non-myeloma cell lines, cataloging a total of 57 potent multiple myeloma survival genes. We identified the Bcl2 family member MCL1 and several 26S proteasome subunits among the most important and selective multiple myeloma survival genes. These results provided biologic validation of our screening strategy. Other essential targets included genes involved in RNA splicing, ubiquitination, transcription, translation, and mitosis. Several of the multiple myeloma survival genes, especially MCL1, TNK2, CDK11, and WBSCR22, exhibited differential expression in primary plasma cells compared with other human primary somatic tissues. Overall, the most striking differential functional vulnerabilities between multiple myeloma and non-multiple myeloma cells were found to occur within the 20S proteasome subunits, MCL1, RRM1, USP8, and CKAP5. We propose that these genes should be investigated further as potential therapeutic targets in multiple myeloma.
UR - http://www.scopus.com/inward/record.url?scp=84863012484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863012484&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-11-2781
DO - 10.1158/0008-5472.CAN-11-2781
M3 - Article
C2 - 22147262
AN - SCOPUS:84863012484
SN - 0008-5472
VL - 72
SP - 757
EP - 768
JO - Cancer research
JF - Cancer research
IS - 3
ER -